FOLH1 and prostate carcinoma: Most recently, Giangrande and colleagues addressed this issue by optimizing their previous PSMA-siRNA chimeric design to achieve enhanced inhibition of prostate cancer xenograft growth via systemic administration (Figure 1c) [17].